Semaglutide in HFpEF across an obesity class and by reducing body weight: a preselected analysis of the STEP-HFpEF trial.

competing interests

BAB receives research support from the National Institutes of Health (NIH) and the US Department of Defense as well as research grant funding from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, Rivus and Tenax Therapeutics. BAB has also served as a consultant to Actelion, Amgen, Aria, Axon Therapies, BD Biosciences, Boehringer Ingelheim, Cytokinetics, Edwars Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM Biopharmaceuticals, NXT, and VADovations. Inventor (US Patent No. 10,307,179) of tools and approach for minimally invasive pericardial modification for the treatment of heart failure. DWK has been supported, in part, by the Kermit Glenn Phillips II Chair in Cardiovascular Medicine and NIH grants U01AG076928, R01AG078153, R01AG045551, R01AG18915 and U01HL160272 and reports receiving fees as a consultant to Bayer, Corvia Medical, Boehringer Ingelheim, Ketyo, Rivus, Novo Nordisk, AstraZeneca, Pfizer, and Novartis; Grant funding from Novartis, Bayer, Novo Nordisk, Revos, Pfizer, and AstraZeneca; and stock ownership in Gilead Sciences. MJD has served as a consultant, advisory board member, and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; advisory board member and spokesperson for AstraZeneca; Member of the Advisory Board of Pfizer, Medtronic, and ShouTi Pharma Inc.; Spokesperson for Novartis, Sanofi and Amgen. MD has received grants to support trials initiated by investigators and investigators from AstraZeneca, Sanofi-Aventis, Eli Lilly, Boehringer Ingelheim, Janssen, and Novo Nordisk. JB is a consultant to ABBOTT, American Regent, Amgen, Applied Therapic, Astrazneca, Bayer, Boehringer igelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRX, Cyto Kinetics, Edwars, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, and Lexicon. and Eli Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, 3live, and Vifor. MCP has received research grants or consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Napp Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Roche, and SQ Innovations; served on committees for AbbVie, Akero, Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, New Amsterdam, Novo Nordisk, Resverlogix and Teikoku; He is the Director of Global Clinical Trials Partners. SJS reports receiving consulting fees from Abbott, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Imara, Impulse Dynamics, Intellia, Ionis, Eli Lilly, Merck, Metabolic Flux, Myocardia, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Revos, Sardocor, Shevamed, Tenax, Tenaya and United Therapeutics. SV reports on fees and/or advisory fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, Novartis, Merck, PhaseBio, HLS Therapeutics, Amarin, Eli Lilly, Janssen, Pfizer, TIMI, the Canadian Medical and Surgical Knowledge Translation Research Group . WA provides fees and/or consulting fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, and Novo Nordisk. FZA advertises fees and/or advisory fees from Abbott, AstraZeneca, Medtronic, Novo Nordisk, Occlutech, Pharmacosmos, and Vifor. VC reports speaker fees from AstraZeneca, Boehringer Ingelheim, Cipla, Dr. Reddy’s, Lupin’s, Novartis, Novo Nordisk, Mankind, Pfizer, Sanofi, Sun Pharma, and Torrent. JE indicates trial lead research support from American Regent, Applied Therapeutics, Bayer, Cytokinetics, Merck, and Novo Nordisk; advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, and Otsuka; and serving as a consultant for US2.ai. MF reports no conflicts of interest. HI advertises fees and/or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Mochida, Novartis, and Novo Nordisk. ML reports fees and/or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Ewopharma, Gedeon Richter, Novartis, Novo Nordisk, Roche and Servier. VM announces consulting fees from Bayer, Merck Sharp & Dohme, and Novo Nordisk; research grants from Regeneron; and research support from the National Institute for Research in Metabolic and Cardiovascular Diseases (EXCELES Programme, Project No. LX22NPO5104), funded by the European Union – Next Generation EU. JN advertises fees and/or advisory fees from Alleviant, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Pfizer, Novartis, Novo Nordisk, Rovi, and Vifor. The EP offers a fee from Novo Nordisk. M. Schou reports on speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, and Novo Nordisk. M. Senni provides fees and/or consulting fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Vifor. PvdM reports institutional payments for advisory fees and/or grants from AstraZeneca, Boehringer Ingelheim, BridgeBio, Ionis, Novartis, Novo Nordisk, Pfizer, Pharmacosmoc, Pharma Nord, and Vifor. DVL advertises fees and/or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Novo Nordisk, Recardio, Sanofi, Sanova, and Vaxxinity. DW reports on advisory fees from Novo Nordisk. SR, EB, MNE, GKH and DVM are employees of and shareholder in Novo Nordisk A/SMNK and serve as a consultant or on the advisory board of 35Pharma, Alnylam, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics and Dexcom. , Eli Lilly, Esperion Therapeutics, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes & Cardiovascular), Novo Nordisk, Pharmacosmos, Pfizer, SC Pharmaceuticals, Sanofi, Structural Therapies, Favour and Youngen Therapeutics. MNK has also received research grants from AstraZeneca, Boehringer Ingelheim, and Pfizer; owns shares in Artera Health and Saghmos Therapeutics; received fees from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; And he received further research support from AstraZeneca.